Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Conductor Daniel Barenboim says he has been diagnosed with Parkinson's disease. The 82-year-old issued a statement Thursday ...

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

The renowned musician says he plans to keep playing, after confirming the long-suspected diagnosis.

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

All aboard the "Crazy Train" — Black Sabbath will be reuniting for a performance in Ozzy Osbourne's hometown of Birmingham, U ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...